Impact Therapeutics Inc: IMPACT Therapeutics is a privately held clinical-stage biopharmaceutical company and dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. We have assembled a highly differentiated and de-risked pipeline highlighted with three most advanced compounds in targets with proof-of-concept validation and superior drug properties over competitors. With three compounds in clinical stage including PARP inhibitor in pivotal studies, we possess leading global DNA damage response (DDR) pipeline with the most synthetic lethality clinical compounds among biotech companies. Meanwhile, we are expanding drug discovery platform to other novel synthetic lethality targets. Financed by recognized venture capitals including Lilly Asia Ventures and led by experienced management team, IMPACT established fully functioned R&D and operation in China and US.

Senaparib (IMP4297) is a novel agent targeting PARP (poly-ADP ribose polymerase) developed by IMPACT. Early clinical data showed the potential to be the best-in-class PARP inhibitor with better safety profile and wider therapeutic window. These enable Senaparib more suitable for long-term therapies and combination therapies. IMPACT and Junshi Biosciences established a 50:50 joint venture that focuses on the development and commercialization of Senaparib in China. The JV is currently conducting a Phase II pivotal study and a Phase III study of Senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. Outside China, IMPACT alone is conducting a Phase I/II study of Senaparib and temozolomide combination therapy in solid tumors and small cell lung cancer treatment, as well as a Phase II study of Senaparib monotherapy in prostate cancer maintenance treatment.